Replies to post #163940 on Biotech Values

[ciotera]

there's no late-stage data in GT1B to support this filing.

I think there is enough evidence that GT1b is easier to cure (vs. GT1a), so GILD is exploiting this in the GT1b heavy Russian market.

Japan is another one, but it's not price constrained, so this strategy is less relevant there.